

Cristina Nanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8138632/publications.pdf>

Version: 2024-02-01

205
papers

8,850
citations

41627

51
h-index

53065

89
g-index

211
all docs

211
docs citations

211
times ranked

9085
citing authors

#	ARTICLE	IF	CITATIONS
1	Spine Infections: The Role of Fluorodeoxyglucose Positron Emission Tomography (FDG PET) in the Context of the Actual Diagnosis Guideline. <i>Current Medical Imaging</i> , 2022, 18, 216-230.	0.4	2
2	Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	0.8	85
3	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015.	3.3	35
4	Imaging Techniques in Staging and Early Phases. , 2021, , 53-66.		0
5	18F-FDG PET-CT in Treatment Response Evaluation: Multiple Myeloma. , 2021, , 395-401.		0
6	The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. <i>Cancers</i> , 2021, 13, 1575.	1.7	4
7	Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. <i>European Journal of Radiology</i> , 2021, 141, 109793.	1.2	16
8	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 390-409.	3.3	7
9	Skeletal Survey in Multiple Myeloma: Role of Imaging. <i>Current Medical Imaging</i> , 2021, 17, 956-965.	0.4	3
10	PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 621-632.	2.5	17
11	Radiological and Nuclear Medicine Imaging of Multiple Myeloma. , 2021, , .		0
12	The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma. <i>Seminars in Nuclear Medicine</i> , 2021, , .	2.5	6
13	[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 579-591.	3.3	39
14	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5406.	1.8	13
15	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. <i>Cancers</i> , 2020, 12, 2532.	1.7	17
16	Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. <i>Cancers</i> , 2020, 12, 659.	1.7	8
17	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3058-3065.	3.3	8
18	Benign albeit glycolytic: MCT4 expression and lactate release in giant cell tumour of bone. <i>Bone</i> , 2020, 134, 115302.	1.4	4

#	ARTICLE	IF	CITATIONS
19	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC). <i>Clinical and Translational Imaging</i> , 2020, 8, 29-38.	1.1	0
20	PET-FDG: Impetus. <i>Cancers</i> , 2020, 12, 1030.	1.7	13
21	Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL. <i>Nuclear Medicine Communications</i> , 2020, 41, 1178-1182.	0.5	0
22	Learned Deep Radiomics for Survival Analysis with Attention. <i>Lecture Notes in Computer Science</i> , 2020, , 35-45.	1.0	1
23	PET/CT with Standard Non-FDG Tracers in Multiple Myeloma. , 2019, , 93-97.		4
24	The Issue of Interpretation. , 2019, , 99-104.		1
25	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	5.1	338
26	Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma. <i>PET Clinics</i> , 2019, 14, 383-389.	1.5	9
27	Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 657.	1.3	0
28	Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study. <i>Cancers</i> , 2019, 11, 713.	1.7	10
29	Sclerosing Angiomatoid Nodular Transformation of the Adrenal Gland: A Case Report of a Novel Histopathological Entity. <i>Journal of the Endocrine Society</i> , 2019, 3, 1207-1213.	0.1	4
30	Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1661-1671.	3.3	8
31	Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2247-2254.	0.6	4
32	Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i> , 2019, 6, 69.	1.2	34
33	The role of 18F-FDG PET/CT in soft tissue sarcoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 626-631.	0.5	27
34	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 194-205.	3.3	45
35	State-of-the-art imaging techniques in the management of preoperative staging and restaging of prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 18-30.	0.5	16
36	Hybrid Imaging for Gynecologic Malignancies. , 2019, , 881-898.		0

#	ARTICLE	IF	CITATIONS
37	Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. <i>Leukemia and Lymphoma</i> , 2018, 59, 2990-2993.	0.6	8
38	A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. <i>Future Oncology</i> , 2018, 14, 1101-1115.	1.1	8
39	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. <i>IMPeTUs (Italian) Tj ETQq1 1 0.784314 rgBT /Over</i> 712-719.	3.3	95
40	FDG-PET/CT Guided Biopsy in Angiosarcoma of Bone. <i>Clinical Nuclear Medicine</i> , 2018, 43, e48-e49.	0.7	4
41	Vertebral Fractures of Unknown Origin: Role of Computed Tomography-Guided Biopsy. <i>International Journal of Spine Surgery</i> , 2018, 12, 673-679.	0.7	11
42	In Vivo Imaging of Inflammation and Infection. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-2.	0.4	1
43	Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2139-2146.	3.3	38
44	Nuclear Medicine Imaging of Prostate Cancer in the Elderly. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 541-547.	2.5	6
45	Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 305-312.e1.	0.9	19
46	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	0.6	20
47	Prostate cancer imaging and therapy. , 2018, , .		0
48	Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 746-749.	1.4	31
49	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	0.6	21
50	A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. <i>American Journal of Roentgenology</i> , 2017, 209, 152-158.	1.0	29
51	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1878-1887.	3.3	9
52	Therapy assessment in multiple myeloma with PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 111-117.	3.3	14
53	Prostate Cancer Imaging and Therapy. <i>PET Clinics</i> , 2017, 12, i.	1.5	0
54	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394

#	ARTICLE	IF	CITATIONS
55	Prostate Cancer Imaging in the Era of Molecular Medicine. PET Clinics, 2017, 12, xi.	1.5	1
56	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 Biochemically Recurrent Prostate Cancer. Journal of Urology, 2017, 197, 676-683.	0.2	165
57	The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 215-223.	3.3	52
58	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
59	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
60	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 749-775.		0
61	Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. Journal of Nuclear Medicine, 2016, 57, 61S-66S.	2.8	35
62	PET Tracers Beyond FDG in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 507-521.	2.5	62
63	PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2103-2104.	3.3	7
64	The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies. PET Clinics, 2016, 11, 285-296.	1.5	7
65	18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1601-1610.	3.3	204
66	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 414-421.	3.3	92
67	18F-FDG PET/CT for Bone and Soft Tissue Biopsy. , 2016, , 87-93.		0
68	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2016, , 1-27.		0
69	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	0.6	0
70	11C-Meta-Hydroxyephedrine. Clinical Nuclear Medicine, 2015, 40, e96-e103.	0.7	14
71	68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. Clinical Nuclear Medicine, 2015, 40, e132-e133.	0.7	9
72	18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse. Clinical Nuclear Medicine, 2015, 40, e386-e391.	0.7	118

#	ARTICLE	IF	CITATIONS
73	Cardiac resynchronization therapy and cardiac sympathetic function. <i>European Journal of Clinical Investigation</i> , 2015, 45, 792-799.	1.7	18
74	Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment. <i>Nanomedicine</i> , 2015, 10, 3483-3494.	1.7	57
75	The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1068-1073.	2.0	46
76	FDG PET/CT for bone and soft-tissue biopsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1333-1334.	3.3	10
77	PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4384-4390.	3.2	140
78	Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. <i>Nuclear Medicine and Biology</i> , 2015, 42, 858-863.	0.3	11
79	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. <i>Blood</i> , 2015, 126, 5009-5009.	0.6	0
80	Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study. <i>PLoS ONE</i> , 2014, 9, e108112.	1.1	91
81	First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 239.	0.4	8
82	Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice. <i>Cancer Biology and Therapy</i> , 2014, 15, 1219-1225.	1.5	21
83	Anti-1-Amino-3- ¹⁸ F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1986-1992.	2.8	138
84	Nuclear medicine in urological cancers: what is new?. <i>Future Oncology</i> , 2014, 10, 2061-2072.	1.1	3
85	Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning. <i>Clinical Nuclear Medicine</i> , 2014, 39, e367-e374.	0.7	28
86	Usefulness of 64Cu-ATSM in Head and Neck Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e59-e63.	0.7	36
87	First Case of ¹⁸ F-FACBC PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse after Radical Prostatectomy for Prostate Cancer and Negative ¹¹ C-Choline PET/CT: New Imaging Techniques May Expand Pioneering Approaches. <i>Urologia Internationalis</i> , 2014, 92, 242-245.	0.6	19
88	The Use of Gallium-68 Labeled Somatostatin Receptors in PET/CT Imaging. <i>PET Clinics</i> , 2014, 9, 323-329.	1.5	45
89	18F-FDG PET/CT impact on testicular tumours clinical management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 668-673.	3.3	60
90	FDG PET/CT in autoimmune pancreatitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1264-1265.	3.3	5

#	ARTICLE	IF	CITATIONS
91	Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. <i>BMC Research Notes</i> , 2014, 7, 32.	0.6	32
92	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1617-1623.	3.3	79
93	FDG and other radiopharmaceuticals in the evaluation of liver lesions. <i>Clinical and Translational Imaging</i> , 2014, 2, 115-127.	1.1	2
94	Performance of FDG PET/ceCT in the evaluation of patients with lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 219-223.	2.5	4
95	18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 106-110.	0.9	68
96	Positron Emission Tomography With Computed Tomography-Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e101-e104.	0.2	10
97	Reactive follicular lymphoid infiltrate: A new condition to exclude in patients with PET positivity inside the heart. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 402-405.	1.4	0
98	Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study. <i>Current Radiopharmaceuticals</i> , 2014, 7, 107-114.	0.3	3
99	¹¹ C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. <i>Current Radiopharmaceuticals</i> , 2014, 7, 79-83.	0.3	5
100	Molecular Imaging and Tumoral Antigen Targeting. <i>Medical Radiology</i> , 2014, , 863-870.	0.0	0
101	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 365-84.	1.0	109
102	Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1356-1364.	3.3	43
103	18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1190-1196.	3.3	63
104	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 642-643.	3.3	0
105	Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 11-17.	3.3	109
106	Usefulness of 11C-Choline Positron Emission Tomography for Genital Chlamydial Infection Assessment in a Balb/c Murine Model. <i>Molecular Imaging and Biology</i> , 2013, 15, 450-455.	1.3	3
107	Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice. <i>Molecular Imaging and Biology</i> , 2013, 15, 194-202.	1.3	12
108	11C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. <i>Molecular Metabolism</i> , 2013, 2, 153-160.	3.0	21

#	ARTICLE	IF	CITATIONS
109	The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 172-178.	2.5	10
110	Applications of Small Animal PET. <i>Recent Results in Cancer Research</i> , 2013, 187, 247-255.	1.8	1
111	The detection of disease relapse after radical treatment for prostate cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 831-833.	0.5	13
112	The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level ≤ 0.5 ng/mL. <i>Clinical Nuclear Medicine</i> , 2013, 38, e342-e345.	0.7	63
113	PET/CT in the Management and Prognosis of Pancreatic Exocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2013, 38, 33-34.	0.7	1
114	The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM). <i>Clinical Nuclear Medicine</i> , 2013, 38, e74-e79.	0.7	65
115	18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis. <i>Clinical Nuclear Medicine</i> , 2013, 38, e171-e177.	0.7	66
116	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigen Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 796-807.	3.2	74
117	Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 729-733.	0.7	11
118	18F-DOPA PET/CT in Neuroblastoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, e73-e78.	0.7	63
119	F-18 FDG PET/CT Detects Muscle Involvement in Erdheim-Chester Disease. <i>Clinical Nuclear Medicine</i> , 2012, 37, 196-197.	0.7	11
120	Potential role of combined FDG PET/CT & contrast enhancement MRI in a rectal carcinoma model with nodal metastases characterized by a poor FDG-avidity. <i>European Journal of Radiology</i> , 2012, 81, 658-662.	1.2	3
121	PET/CT imaging in different types of lung cancer: An overview. <i>European Journal of Radiology</i> , 2012, 81, 988-1001.	1.2	132
122	Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. <i>European Journal of Radiology</i> , 2012, 81, e893-e896.	1.2	106
123	FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1538-1544.	3.3	76
124	Gallium-labelled peptides for imaging of inflammation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 68-77.	3.3	38
125	Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1278-1283.	3.3	34
126	Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 57-71.	3.3	111

#	ARTICLE	IF	CITATIONS
127	Value of FDG PET/CT in Patients with Treated Ovarian Cancer and Raised CA125 Serum Levels. <i>Molecular Imaging and Biology</i> , 2012, 14, 123-129.	1.3	41
128	Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a rat model. <i>Texas Heart Institute Journal</i> , 2012, 39, 488-99.	0.1	16
129	Preclinical Studies with Small Animal PET. <i>PET Clinics</i> , 2011, 6, 71-77.	1.5	1
130	Present and future of PET and PET/CT in gynaecologic malignancies. <i>European Journal of Radiology</i> , 2011, 78, 12-20.	1.2	25
131	When Should F-18 FDG PET/CT Be Used Instead of 68Ga-DOTA-Peptides to Investigate Metastatic Neuroendocrine Tumors?. <i>Clinical Nuclear Medicine</i> , 2011, 36, 1109-1111.	0.7	5
132	I-123 MIBG Scintigraphy and 68Ga-DOTANOC PET/CT Negative But F-18 DOPA PET/CT Positive Pheochromocytoma. <i>Clinical Nuclear Medicine</i> , 2011, 36, 124-126.	0.7	9
133	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. <i>Blood</i> , 2011, 118, 5989-5995.	0.6	445
134	Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <math>< 1.5 \text{ \AA ng/ml}</math>?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 55-63.	3.3	166
135	18F-FDG PET/CT detects systemic involvement in sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2102-2102.	3.3	6
136	Imaging with 11Carbon labelled PET tracers. <i>Nuclear Medicine Communications</i> , 2010, 31, 613-616.	0.5	3
137	68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 722-727.	3.3	107
138	Imaging with non-FDG PET tracers: outlook for current clinical applications. <i>Insights Into Imaging</i> , 2010, 1, 373-385.	1.6	13
139	Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. <i>Molecular Imaging and Biology</i> , 2010, 12, 616-625.	1.3	17
140	⁶⁸ Ga-Citrate PET/CT for Evaluating Patients with Infections of the Bone: Preliminary Results. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1932-1936.	2.8	118
141	Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 673-681.	1.9	27
142	⁶⁸ Ga-DOTANOC PET/CT Allows Somatostatin Receptor Imaging in Idiopathic Pulmonary Fibrosis: Preliminary Results. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1950-1955.	2.8	60
143	FDG-PET and PET/CT for Evaluating Soft Tissue Sarcomas. <i>PET Clinics</i> , 2010, 5, 341-347.	1.5	5
144	⁶⁸ Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 669-673.	2.8	227

#	ARTICLE	IF	CITATIONS
145	Molecular Imaging and Tumoural Antigen Targeting. Medical Radiology, 2010, , 871-878.	0.0	0
146	Non FDG PET. Clinical Radiology, 2010, 65, 536-548.	0.5	47
147	CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance. Cell Metabolism, 2010, 11, 273-285.	7.2	190
148	Preclinical evaluation of KIT/PDGFR α and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. Journal of Experimental and Clinical Cancer Research, 2010, 29, 173.	3.5	31
149	¹¹ C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. Tumori, 2009, 95, 382-384.	0.6	28
150	Small Animal PET in Oncology: The Road from Bench to Bedside. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 277-285.	0.7	13
151	Influence of Trigger PSA and PSA Kinetics on ¹¹ C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. Journal of Nuclear Medicine, 2009, 50, 1394-1400.	2.8	230
152	Functional and histopathological improvement of the post ∞ infarcted rat heart upon myoblast cell grafting and relaxin therapy. Journal of Cellular and Molecular Medicine, 2009, 13, 3437-3448.	1.6	33
153	Positron-emission tomography in gynaecologic malignancies. Archives of Gynecology and Obstetrics, 2009, 280, 521-528.	0.8	16
154	Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 616-623.	3.3	11
155	Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1940-1943.	3.3	8
156	Small animal PET for the evaluation of an animal model of genital infection. Clinical Physiology and Functional Imaging, 2009, 29, 187-192.	0.5	10
157	A novel model of CCl ₄ -induced cirrhosis with ascites in the mouse. Journal of Hepatology, 2009, 51, 991-999.	1.8	100
158	Synthesis and quality control of ⁶⁸ Ga citrate for routine clinical PET. Nuclear Medicine Communications, 2009, 30, 542-545.	0.5	38
159	Late FDG PET Normalization After Radioimmunotherapy in a Patient With Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2009, 34, 777-778.	0.7	1
160	⁶⁸ Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nuclear Medicine Communications, 2009, 30, 281-286.	0.5	89
161	¹¹ C-methionine vs. ¹⁸ F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results. In Vivo, 2009, 23, 105-110.	0.6	12
162	Could choline PET play a role in malignancies other than prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 216-218.	3.3	3

#	ARTICLE	IF	CITATIONS
163	Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1431-1438.	3.3	254
164	Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. <i>Annals of Nuclear Medicine</i> , 2008, 22, 429-432.	1.2	6
165	Contouring Carcinomas by FDG-PET: Is the Role of Tumor Biology Underestimated?: In Regard to MacManus et al. (<i>Int J Radiat Oncol Biol Phys</i> 2008;71:24). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 303-304.	0.4	2
166	Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 667-671.	2.5	82
167	Applications of Small Animal Imaging with PET, PET/CT, and PET/MR Imaging. <i>PET Clinics</i> , 2008, 3, 243-250.	1.5	6
168	¹⁸ F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 681-690.	0.7	29
169	68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. <i>Nuclear Medicine Communications</i> , 2008, 29, 415-417.	0.5	16
170	Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. <i>Nuclear Medicine Communications</i> , 2008, 29, 705-710.	0.5	8
171	Distal Esophagus: Evaluation with 18F-FDG PET/CT Fusion Imaging. , 2008, , 55-61.		0
172	18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. <i>In Vivo</i> , 2008, 22, 513-7.	0.6	61
173	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. <i>Haematologica</i> , 2007, 92, 50-55.	1.7	318
174	18F-DOPA PET and PET/CT. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1577-1579.	2.8	120
175	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 1322-1330.	3.2	126
176	Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. <i>Nuclear Medicine Communications</i> , 2007, 28, 547-553.	0.5	32
177	Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. <i>Nuclear Medicine Communications</i> , 2007, 28, 647-652.	0.5	14
178	Role of small animal PET in stimulating the development of new radiopharmaceuticals in oncology. <i>Nuclear Medicine Communications</i> , 2007, 28, 427-429.	0.5	7
179	Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , 2007, 28, 473-477.	0.5	45
180	Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. <i>Nuclear Medicine Communications</i> , 2007, 28, 589-595.	0.5	168

#	ARTICLE	IF	CITATIONS
181	Epithelial and Mesenchymal Tumor Compartments Exhibit In Vivo Complementary Patterns of Vascular Perfusion and Glucose Metabolism. <i>Neoplasia</i> , 2007, 9, 900-908.	2.3	24
182	Positron Emission Tomography and Thyroid Cancer. <i>PET Clinics</i> , 2007, 2, 295-304.	1.5	3
183	The Evolving Role of Positron Emission Tomography in Patients with Medullary Thyroid Carcinoma. <i>PET Clinics</i> , 2007, 2, 305-311.	1.5	3
184	11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 68.	0.8	97
185	Performance evaluation of a small animal PET scanner. Spatial resolution characterization using 18F and 11C. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2007, 571, 215-218.	0.7	10
186	FDG small animal PET permits early detection of malignant cells in a xenograft murine model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 755-762.	3.3	25
187	Role of small animal PET for molecular imaging in pre-clinical studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1819-1822.	3.3	13
188	11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1704-1705.	3.3	25
189	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2096-2101.	0.6	54
190	Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1048-1052.	0.6	5
191	Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 409-413.	2.5	46
192	Clinical PET in oncology: not only FDG. <i>Nuclear Medicine Communications</i> , 2006, 27, 685-688.	0.5	4
193	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 525-531.	3.3	135
194	11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 453-459.	3.3	49
195	18F-DOPA PET/CT and neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 509-513.	3.3	23
196	Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. <i>Nuclear Medicine Communications</i> , 2005, 26, 689-694.	0.5	88
197	Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. <i>Nuclear Medicine Communications</i> , 2005, 26, 827-830.	0.5	31
198	18F-FDG PET in malignant lymphoma: significance of positive findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 749-756.	3.3	62

#	ARTICLE	IF	CITATIONS
199	Value of PET-CT fusion imaging in avoiding potential pitfalls in the interpretation of 18F-FDG accumulation in the distal oesophagus. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 990-992.	3.3	14
200	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3492-3492.	0.6	0
201	Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1642-9.	2.8	178
202	Role of 18F-FDG PET for Evaluating Malignant Pleural Mesothelioma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 149-154.	0.7	30
203	¹⁸ F-FDG PET Early After Radiotherapy in Lymphoma Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 606-612.	0.7	24
204	Scintigraphic Findings in Necrotizing Myopathy. <i>Clinical Nuclear Medicine</i> , 2003, 28, 118-120.	0.7	1
205	Somatostatin Receptor Scintigraphy for Bronchial Carcinoid Follow-Up. <i>Clinical Nuclear Medicine</i> , 2003, 28, 548-552.	0.7	32